Fomichev Dmitry, Kalinin Pavel, Kutin Maxim, Sharipov Oleg
Department of Skull-Base Surgery, Burdenko Neurosurgical Institute, Moscow, Russia.
Department of Skull-Base Surgery, Burdenko Neurosurgical Institute, Moscow, Russia.
World Neurosurg. 2016 Oct;94:181-187. doi: 10.1016/j.wneu.2016.06.124. Epub 2016 Jul 9.
The endoscopic extended transsphenoidal approach for suprasellar craniopharyngiomas may be a really alternative to the transcranial approach in many cases. The authors present their experience with this technique in 136 patients with craniopharyngiomas.
From the past 7 years 204 patients with different purely supradiaphragmatic tumors underwent removal by extended endoscopic transsphenoidal transtuberculum transplanum approach. Most of the patients (136) had craniopharyngiomas (suprasellar, intra-extraventricular). The patients were analyzed according to age, sex, tumor size, growth and tumor structure, and clinical symptoms. Twenty-five patients had undergone a previous surgery. The mean follow-up was 42 months (range, 4-120 months). The operation is always performed with the bilateral endoscopic endonasal anterior extended transsphenoidal approach.
A gross-total removal was completed in 72%. Improvement of vision or absence of visual deterioration after operation was observed in 89% of patients; 11% had worsening vision after surgery. Endocrine dysfunction did not improve after surgery, new hypotalamopituitary dysfunction (anterior pituitary dysfunction or diabetes insipidus) or worsening of it was observed in 42.6%. Other main complications included transient new mental disorder in 11%, temporary neurological postoperative deficits in 3.7%, bacterial meningitis in 16%, cerebrospinal fluid leaks in 8.8%. The recurrence rate was 20% and the lethality was 5.8%.
Resection of suprasellar craniopharyngiomas using the extended endoscopic approach is a more effective and less traumatic technology, able to provide resection of the tumor along with high quality of life after surgery, and relatively rare postoperative complications and mortality.
对于鞍上颅咽管瘤,内镜扩大经蝶入路在很多情况下可能是经颅入路的一种切实可行的替代方法。作者介绍了他们对136例颅咽管瘤患者采用该技术的经验。
在过去7年中,204例不同类型的单纯膈上肿瘤患者接受了内镜扩大经蝶经结节经筛板入路切除术。大多数患者(136例)患有颅咽管瘤(鞍上、脑室内外)。根据年龄、性别、肿瘤大小、生长情况、肿瘤结构和临床症状对患者进行分析。25例患者曾接受过一次手术。平均随访时间为42个月(范围4 - 120个月)。手术均采用双侧内镜鼻内扩大经蝶入路进行。
72%的患者实现了肿瘤全切。89%的患者术后视力改善或未出现视力恶化;11%的患者术后视力恶化。术后内分泌功能障碍未改善,42.6%的患者出现新的下丘脑 - 垂体功能障碍(垂体前叶功能障碍或尿崩症)或原有功能障碍加重。其他主要并发症包括11%的患者出现短暂性新发精神障碍,3.7%的患者出现术后暂时性神经功能缺损,16%的患者发生细菌性脑膜炎,8.8%的患者出现脑脊液漏。复发率为20%,死亡率为5.8%。
采用内镜扩大入路切除鞍上颅咽管瘤是一种更有效且创伤更小的技术,能够在切除肿瘤的同时保证术后较高的生活质量,且术后并发症和死亡率相对较低。